4055-69-0

Basic information

• Product Name: 2,3-DIHYDROXY-4-METHOXYBENZALDEHYDE
• Synonyms: 2,3-DIHYDROXY-4-METHOXYBENZALDEHYDE;4-METHOXY-2,3-DIHYDROXYBENZALDEHYDE;AKOS 235-08;4-METHOXY-2,3-DIHYDROXYBENZALDEHYDE 95%;2 3-DIHYDROXY-4-METHOXYBENZALDEHYDE 95%
• CAS NO: 4055-69-0
• Molecular Formula: C₈H₈O₄
• Molecular Weight: 168.15
• Product Categories: Aromatic Aldehydes & Derivatives (substituted)
• Mol File: 4055-69-0.mol
• Article Data: 24

Chemical Properties

• Melting Point: 69.5 °C
• Boiling Point: 299.047 °C at 760 mmHg
• Flash Point: 123.631 °C
• Appearance: /
• Density: 1.378 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 7.63±0.15(Predicted)
• CAS DataBase Reference: 2,3-DIHYDROXY-4-METHOXYBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIHYDROXY-4-METHOXYBENZALDEHYDE(4055-69-0)
• EPA Substance Registry System: 2,3-DIHYDROXY-4-METHOXYBENZALDEHYDE(4055-69-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36-43
• Safety Statements: 26-36/37
• Hazardous Substances Data: 4055-69-0(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Synthetic Communications, 16, p. 645, 1986 DOI: 10.1080/00397918608057734

InChI:InChI=1/C8H8O4/c1-12-6-3-2-5(4-9)7(10)8(6)11/h2-4,10-11H,1H3

Upstream product

• 2103-57-3 2,3,4-trimethoxybenzaldehyde 
• 2144-08-3 2,3,4-trihydroxybenzylaldehyde 
• 77-78-1 dimethyl sulfate 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 
• 3934-84-7 3,4-dihydroxy-5-methoxybenzoic acid 
• 160820-49-5 6-methoxy-7-methoxymethoxy-2-methylbenzo[b]furan 
• 88367-32-2 7-hydroxy-6-methoxy-2-methylbenzo[b]furan 
• 160820-50-8 2-hydroxy-4-methoxy-3-methoxymethoxybenzaldehyde 
• 7647-01-0 hydrogenchloride 
• 60-29-7 diethyl ether 
• 934-00-9 3-methocycatechol 
• 122-51-0 orthoformic acid triethyl ester 
• 2973-58-2 2-bromoisovanillin 

Downstream Products

• 19492-03-6 8-hydroxy-7-methoxy-2H-chromen-2-one 
• 84018-98-4 3-Hydroxy-4-methoxy-2-((2E,6E)-3,7,11-trimethyl-dodeca-2,6,10-trienyloxy)-benzaldehyde 
• 84018-86-0 2-Hydroxy-4-methoxy-3-((2E,6E)-3,7,11-trimethyl-dodeca-2,6,10-trienyloxy)-benzaldehyde 
• 84018-99-5 4-Methoxy-2,3-bis-((2E,6E)-3,7,11-trimethyl-dodeca-2,6,10-trienyloxy)-benzaldehyde 
• 88367-27-5 3-Methoxy-6-methylbenzene-1,2-diol 
• 84018-96-2 2-Allyloxy-3-hydroxy-4-methoxy-benzaldehyde 
• 84018-89-3 3-Allyloxy-2-hydroxy-4-methoxy-benzaldehyde 
• 84018-90-6 2,3-Bis-allyloxy-4-methoxy-benzaldehyde 
• 189700-15-0 (2,3-Bis-benzyloxy-4-methoxy-phenyl)-methanol 
• 189700-16-1 2,3-Bis-benzyloxy-1-chloromethyl-4-methoxy-benzene 
• 189700-18-3 (S)-2-Amino-3-(2,3-bis-benzyloxy-4-methoxy-phenyl)-propionic acid methyl ester 
• 189700-17-2 (2S,5R)-2-(2,3-Bis-benzyloxy-4-methoxy-benzyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydro-pyrazine 
• 189700-19-4 (S)-3-(2,3-Bis-benzyloxy-4-methoxy-phenyl)-2-(3-trifluoromethyl-benzoylamino)-propionic acid methyl ester 
• 189700-08-1 (S)-3-(2,3-Dihydroxy-4-methoxy-phenyl)-2-(3-trifluoromethyl-benzoylamino)-propionic acid methyl ester 

Relevant articles and documents

Synthesis and biological evaluation of 10-benzyloxy-Narciclasine

A chemoenzymatic convergent synthesis of 10-benzyloxy narciclasine from bromobenzene was accomplished in 16 steps. The key transformations included toluene dioxygenase-mediated hydroxylation, nitroso Diels-Alder reaction and intramolecular Heck cyclization. The unnatural derivative of narciclasine was subjected to biological evaluation and its activity was compared to other C-10 and C-7 compounds prepared previously.

Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia

The natural products combretastatin A-1 (CA1) and combretastatin A-4 (CA4) function as potent inhibitors of tubulin polymerization and as selective vascular disrupting agents (VDAs) in tumors. Bioreductively activatable prodrug conjugates (BAPCs) can enha

3-substituted coumarin derivatives and their use

The invention provides a 3-substituted coumarin derivative, and pharmaceutically acceptable salts, solvates, hydrates or crystal forms thereof. The above compound has a high calcium flow activity and a very good selectivity on a human derived cannabinoid receptor CB2, and is a specific agonist or inverse agonist of the cannabinoid receptor CB2. The compound is an active ligand of a novel cannabinoid II receptor CB2, and compounds of the above kind and pharmaceutically acceptable salts, solvates, hydrates or crystal forms thereof have high calcium flow activities and a very good selectivity on the human derived cannabinoid receptor CB2. The compound is the specific agonist or inverse agonist of the cannabinoid receptor CB2, and can be applied to the preparation of medicines for treating, preventing and inhibiting CB2 receptor mediated diseases. The structure of the derivative is represented by a general formula A shown in the specification.